Brutieridin

Brutieridin: A Comprehensive Reference

1. Identity: Botanical Origin, Chemical Classification, and Natural Sources

1.1 Botanical Source

Brutieridin is derived from Citrus bergamia Risso et Poiteau, also known as "bergamot," a plant belonging to the Rutaceae family, defined as a hybrid of bitter orange and lemon. Citrus bergamia is a fruit typical of a limited coastal area of the province of Reggio Calabria, Italy, where both climate and environmental conditions are favorable for its cultivation. Bergamot cultivation is highly sensitive to pedoclimatic soil conditions, thriving primarily in the coastal regions of Calabria, where optimal conditions enhance both the yield and quality.

1.2 Chemical Identity

Brutieridin is a flavanone glycoside. More precisely, brutieridin (compound 1) is the 3-hydroxy-3-methylglutaryl neohesperidoside of hesperetin, isolated and detected from the fruits of bergamot (Citrus bergamia). Bergamot comprises two 3-hydroxymethylglutaryl (HMG) derivatives of naturally occurring flavonoid glycosides — brutieridin and melitidin. These glycosides are the HMG derivatives of glucosylated hesperetin and naringenin, respectively, and have a structural similarity to the commercially available HMG-CoA reductase inhibitors known as the statins.

The chemical structures of the purified constituents were identified on the basis of spectroscopic elucidation, including 1D- and 2D-NMR, UV, IR, and mass spectrometric analysis. Structures were elucidated using advanced spectroscopic techniques, including HRESIMS and NMR, confirming specific functional groups and molecular connections.

1.3 Occurrence in the Bergamot Fruit

Bergamot juice is mostly characterized by flavonoids — naringin, neohesperidin, neoeriocitrin, melitidin, and brutieridin. Approximately 300–500 ppm of brutieridin and 150–300 ppm of melitidin are found in bergamot juice.

Brutieridin is found not only in the juice but also in different anatomical portions of the fruit. Bergamot portions — albedo/flavedo, seeds, and juice — all showed high concentrations of flavanones, including melitidin and brutieridin. Research on the albedo (the white pith layer) has been particularly significant: albedo and flavedo extracts contain brutieridin in ripe fruits at 112 ± 15 and 190 ± 9 mg/kg for albedo and flavedo respectively; in unripe fruits, concentrations are 77.4 ± 4.3 and 103 ± 8 mg/kg respectively.

Though most citrus fruits are known to contain flavonoids, the bergamot is unique in that it contains an especially high content of flavonoids. Flavone O-glycosides identified in bergamot include brutieridin, melitidin, rhoifolin 4′-O-glucoside, chrysoeriol 7-O-neohesperidoside-4′-O-glucoside, diosmin, rhoifolin, chrysoeriol 7-O-neohesperidoside, narirutin, and neodiosmin.

More recently, a related HMG-flavanone compound has been discovered. A new flavonoid from bergamot fruit carrying the 3-hydroxy-3-methylglutaryl (HMG) ester moiety has been characterized; named peripolin, it features the HMG chemical group linked to the sugar portion of neoeriocitrin, and its structure was elucidated using high-resolution mass spectrometry and nuclear magnetic resonance experiments.

1.4 Common Forms and Preparations

Brutieridin is not typically marketed or studied as a fully isolated single compound. The majority of current research has been conducted on Bergamot Polyphenolic Fraction (BPF), a mixture of flavonoids including brutieridin. The direct effects of isolated brutieridin have not been conclusively established. The BPF is the primary commercial and research preparation. BPF obtained from the juice and peels of bergamot (Citrus bergamia Risso et Poiteau) fruits is characterized by a unique profile of flavonoids — naringin, brutieridin, and melitidin — along with many other flavonoid and non-flavonoid compounds with lipid-lowering, anti-inflammatory, proautophagic, and detoxifying activity.

An important finding with industrial implications came from research on the albedo waste stream. Bergamot albedo — the white tissues between the skin and the pulp — is a polluting waste in the production of the renowned bergamot fragrance and is easily available by simple industrial processes. The best results for extraction in terms of simplicity and accessibility were obtained with hot water at 65 °C. Interestingly, tea beverages enriched with the two active principles have been obtained by simple addition of dried albedo into commercial tea bags. This hot-water extraction method represents a practical, low-cost avenue for obtaining brutieridin-containing preparations from what was previously considered waste.

2. Traditional and Historical Use

2.1 Origins and Folk Medicine in Calabria

Bergamot citrus species, growing abundantly in the Calabria region of southern Italy, has been used in Calabrian folk medicine to treat cardiovascular ailments for centuries. Bergamot, mainly produced in the Ionian coastal areas of Southern Italy (Calabria), has been used since 1700 for its balsamic and medicinal properties.

Due to its particular fragrance, bergamot was initially used primarily by the perfume industry to produce perfumed waters known as "bergamot water" or "cologne water." In addition, it has been utilized for flavoring by the food and confectionery industries, including the pharmaceutical industry to improve the smell of ointments and medicines, as well as for making toothpaste, hair oils, and cosmetic products.

In the eighteenth century, bergamot oil was added in drops to tea as an antimalarial, and it was further administered to treat scabies, as a sedative, and in drops to prevent insomnia. In folk records from Calabria, bergamotto (Citrus bergamia Risso) was used among other plant remedies in folk medicine practices documented in the region.

In Calabrian ethnographic records, squashed pulp of Citrus bergamia has been used as a folk remedy applied directly to the skin, reflecting the region's reverence for the natural world and its inherent healing powers; this method was often used in urgent situations when there was insufficient time to prepare decoctions or infusions.

2.2 Important Distinction: Traditional Use vs. Brutieridin

It is critical to note that brutieridin — as an isolated chemical compound — was not identified until 2009. Brutieridin was discovered in bergamot orange juice and exhibits statin-like properties in preclinical research. Therefore, all historical and traditional use references pertain to preparations of bergamot fruit (juice, peel, essential oil, or albedo) that contain brutieridin as a constituent, not to brutieridin itself as a recognized entity. The compound was unknown to traditional practitioners, and its characterization belongs entirely to modern phytochemistry.

3. Key Constituents and Active Compounds

3.1 Structural Features of Brutieridin

Brutieridin is structurally characterized by the combination of a flavanone aglycone (hesperetin) with a neohesperidoside sugar moiety that carries an esterified 3-hydroxy-3-methylglutaryl (HMG) group. Brutieridin is a prominent bergamot flavanone O-glycoside that contains the HMG moiety covalently linked to glucose via esterification of carbon 6ʹ hydroxyl group. According to molecular modeling studies, HMG-flavanone O-glycosides or relative metabolites containing HMG moiety can fit into the catalytic pocket of HMG-CoA reductase and mimic the substrate.

The investigated flavonoid conjugates brutieridin and melitidin were recently quantified in bergamot fruit extracts and identified to be structural analogues of statins, lipids concentration lowering drugs that inhibit HMGR. Its companion compound melitidin has an analogous structure but is derived from naringenin rather than hesperetin. BPF contains brutieridin and melitidin, which are 3-hydroxy-3-methylglutaryl derivatives of hesperetin and naringenin, respectively.

3.2 Co-occurring Active Compounds in BPF

In research and supplement preparations, brutieridin always appears alongside a broader matrix of bergamot flavonoids. Several pharmacological and intervention studies have reported that bergamot juice or its enriched polyphenolic fraction (BPF) — obtained from the peeled fruit and mainly composed of flavanones (such as naringenin, hesperetin, eriodictyol glycosides), flavones (apigenin, luteolin, chrysoeriol, diosmetin glycosides), and their 3-hydroxy-3-methylglutaryl (HMG) derivatives — has hypolipemic, hypoglycemic, and anti-inflammatory activities.

4. Mechanisms of Action

4.1 HMG-CoA Reductase (HMGR) Inhibition — The Primary Proposed Mechanism

The most extensively studied and theoretically compelling mechanism for brutieridin is inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR), the rate-limiting enzyme in the cholesterol biosynthesis pathway — the same enzyme targeted by statin drugs. Brutieridin and melitidin have been identified as structural analogues of statins. Density functional theory was applied to study the binding mode of these new flavonoids as possible inhibitors of HMGR, an enzyme that catalyzes the four-electron reduction of HMGCoA to mevalonate — the committed step in the biosynthesis of sterols.

The main active compounds in bergamot, such as melitidin and brutieridin, share structural features with the HMG component of statins, which may explain their affinity for HMG-CoA reductase and contribute to their cholesterol-lowering properties. The BPF contains brutieridin and melitidin — two unique compounds — which bind directly to the enzyme's active site and effectively improve the LDL-C/HDL-C ratio.

Cell-based experiments have provided supporting evidence: in vitro studies using HepG2 hepatoma cells demonstrated that these compounds reduced intracellular cholesterol synthesis by 30–40%.

An important caveat regarding this mechanism has been raised in the peer-reviewed literature. There is not any in vitro or in vivo study that conclusively supports the HMGR inhibition mechanism in isolation for brutieridin and melitidin alone. Most data derives from BPF as a mixture, not from isolated brutieridin.

4.2 Additional Proposed Mechanisms

Bergamot polyphenolic fraction has been demonstrated to improve lipid metabolism by different mechanisms of action: inhibition of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase (naringin, brutieridin, and melitidin), modulation of expression and activity of acyl-CoA oxidase, stearoyl-CoA desaturase 1, and liver-fatty acid binding protein (flavolignans), inhibition of acyl CoA:cholesterol O-acyltransferase (naringin, hesperidin), binding of biliary salts, and improving faecal excretion of sterols.

The hypolipidemic effect of BPF is related to the selective inhibition of the hydroxymethylglutaryl CoA reductase and to the reduction of the activity of phosphatidate phosphohydrolase enzymes, whereas the hypoglycemic action is associated with the increase of the activities of AMP kinase, sirtuin-1 and, in muscle cells and liver, glucose transporter GLUT-4.

Bergamot also contributes to triglyceride reduction by inhibiting acyl-CoA cholesteryl acyltransferase (ACAT) and microsomal triglyceride transfer protein (MTP) — two enzymes involved in lipoprotein assembly.

A significant reduction of cholesterol absorption has been demonstrated to occur following supplementation with BPF, an effect which seems to be related to the inhibition of pancreatic cholesterol ester hydrolase (pCEH). Fecal sterol excretion was found to be increased in hyperlipidemic rats, an effect enhanced by bergamot juice and BPF. The increase in the excretion of bile acids seems to activate cholesterol 7R-hydroxylase, enhancing the conversion of liver cholesterol to bile acids for excretion. This leads to a decrease in hepatic cholesterol content, which in turn stimulates LDL receptor expression and lowers blood cholesterol levels.

In vitro mechanistic studies have provided evidence that polyphenols from bergamot can alter the function of AMPK and pancreatic cholesterol ester hydrolase (pCEH).

4.3 Antioxidant Mechanisms

The antioxidant ability of brutieridin was tested by classical chemical approaches, such as DPPH, ABTS, and FRAP assays, and from a theoretical point of view. The in vivo effects attributed to bergamot have been linked to the antioxidant and anti-inflammatory activities of its constituents and to the ability of HMG derivatives, such as melitidin and brutieridin, to bind relevant biological targets.

5. Scientific Evidence by Area of Use

5.1 Lipid Metabolism and Cardiovascular Risk

Animal Models

After successful trials in a rat model which showed a significant reduction in serum cholesterol, triglycerides, and LDL levels, coupled with an increase in HDL levels, researchers next investigated the effect of brutieridin and melitidin in human patients with high LDL and high triglyceride levels.

Human Clinical Evidence

Multiple clinical trials have provided evidence that different forms of orally administered bergamot can reduce total cholesterol and low-density lipoprotein cholesterol. All such trials used BPF (the bergamot polyphenolic fraction), within which brutieridin is one active constituent.

The landmark clinical study by Mollace et al. (2011) published in Fitoterapia is the most widely cited. Mollace et al. (2011) randomized 237 participants with combined hyperlipidemia to 500 mg/day or 1,000 mg/day of bergamot or placebo during 30 days; 69 subjects taking 500 mg/day of BPF obtained significant reductions of total cholesterol, LDL cholesterol, and triglycerides with respect to the placebo group (–21.8 ± 1.40%, –24.1 ± 1.5%, –30.5 ± 3.2%, respectively).

A separate randomized double-blind placebo-controlled study evaluated a different BPF formulation. Patients were enrolled with mixed hyperlipidemia defined as LDL cholesterol > 120 mg/dL and triglycerides > 175 mg/dL, and serum glucose > 110 mg/dL. Subjects in the BPF group received 650 mg taken twice daily, and subjects in the BPF phytosomal formulation group (BPF Phyto) received 500 mg taken twice daily; both for 30 days. BPF decreased total cholesterol from 262 to 196, LDL from 175 to 116, and triglycerides from 252 to 170. Similar results were observed with BPF Phyto: total cholesterol from 261 to 198, LDL from 174 to 113, and triglycerides from 252 to 173. Both formulations showed an increase in HDL, with BPF increasing HDL from 44 to 48 and BPF Phyto from 44 to 50. Decreases in serum glucose were also observed with BPF from 120 to 98 and BPF Phyto from 124 to 96.

A systematic review (Tandfonline, 2019) summarized the breadth of evidence. This review included a total of 31 studies (20 studies in humans with 1,709 subjects and 11 in animals). In humans, bergamot-derived extract exerts positive effects on hyperlipidemia with an oral dose from 150 mg to 1,000 mg/day of flavonoids administered from 30 to 180 days, demonstrating an effect on body weight and in modulating total cholesterol, triglycerides, LDL, and HDL.

Studies performed in Italy and Australia showed that BPF treatment leads to an important reduction in lipid parameters in the blood of patients with hyperlipidemia, ranging from 15 up to 40% for total cholesterol and LDL-cholesterol. A striking reduction (mean 41.0 ± 2.6%) was also observed for plasma triglyceride levels, accompanied by a significant decrease in blood glucose (22.3 ± 1.0%) in a subgroup of patients with metabolic syndrome.

Combination with Statins

A prospective, open-label, parallel-group, placebo-controlled study enrolled 77 human subjects with elevated LDL and triglycerides who were administered placebo, rosuvastatin 10 mg, rosuvastatin 20 mg, BPF, or BPF with rosuvastatin. The total duration was 30 days, with capsules containing 500 mg of bergamot polyphenolic fraction with 50 mg of ascorbic acid. Both doses of rosuvastatin and BPF reduced total cholesterol, LDL, and urinary mevalonate. The results of this study suggest a combination of rosuvastatin and BPF was safe when taken together for 30 days.

Evidence Limitations

The majority of in vitro and in vivo studies on the statin-like effects of compounds from bergamot have been conducted using a BPF that contains a variety of flavonoids, including brutieridin and melitidin. Research on isolated brutieridin is limited. Additionally, despite encouraging preclinical and clinical data, pharmacokinetic information on bergamot flavonoids in humans remains limited. Most trials are also relatively short in duration (30–120 days) and may involve industry-affiliated researchers, which constitutes a limitation in assessing long-term efficacy and independent replication.

5.2 Non-Alcoholic Fatty Liver Disease (NAFLD) and Hepatic Function

Effects were confirmed in patients treated with BPF, which showed a powerful effect in modulating lipoprotein hepatic traffic and was able to counteract non-alcoholic liver disease (NAFLD).

A clinical study in patients with both metabolic syndrome and NAFLD provided more detailed evidence. There were 107 patients who met the NCEP-ATP III criteria for metabolic syndrome and had ultrasonic evidence of severe NAFLD (hepato-renal index 2.5–3.5) after exclusion of alcohol, viral, and immune disorders. Before and after 120 days of BPF 650 mg twice/day, all patients had full lipid analysis including lipoprotein fractionation by NMR, fasting glucose, ALT, AST, steato test, γ-GT, TNF-α (ELISA), CRP, and ultrasonographic hepatorenal tests. This study represents an important data point on the application of BPF to hepatic endpoints, though brutieridin's specific contribution to these outcomes is not isolated.

5.3 Glucose Metabolism and Metabolic Syndrome

The therapeutic potential of bergamot derivatives has been investigated in human studies: bergamot-derived BPF has beneficial effects in patients with metabolic syndrome, as demonstrated by a concomitant improvement in lipemic and glycemic profiles and by the improvement of altered endothelium-mediated vasodilation.

The hypoglycemic action of BPF is associated with the increase of the activities of AMP kinase, sirtuin-1, and, in muscle cells and liver, glucose transporter GLUT-4. These are mechanistic pathways proposed from in vitro and animal data; their specific attribution to brutieridin alone, as opposed to the full BPF mixture, has not been established in isolation.

5.4 Anti-inflammatory Effects

Different in vitro and in vivo studies have demonstrated bergamot juice's antimicrobial and anticancer properties, which seem to be due to the flavonoids it contains, since the flavonoid-rich fraction of bergamot juice shows antioxidant and anti-inflammatory capabilities and also reduces cancer formation.

The evidence regarding brutieridin's specific anti-inflammatory contribution is largely embedded within research on BPF as a mixture. Individual brutieridin has not been the subject of dedicated clinical anti-inflammatory trials as of current published literature.

5.5 Anticancer / Cancer Stem Cell Research

A notable in vitro and preclinical study examined a 2:1 mixture of brutieridin and melitidin (termed "BMF"). BMF has statin-like properties, which blocks the action of the rate-limiting enzyme for mevalonate biosynthesis (HMGR). BMF functionally inhibits several key characteristics of cancer stem cells (CSCs): it reduced ALDH activity, blocked mammosphere formation, and inhibited the activation of CSC-associated signaling pathways (STAT1/3, Notch, and Wnt/beta-catenin) targeting Rho-GDI-signaling. BMF metabolically inhibited mitochondrial respiration (OXPHOS) and fatty acid oxidation (FAO). Importantly, BMF did not show the same toxic side effects in normal fibroblasts that were observed with statins.

BMF acts as a non-toxic inhibitor of mevalonate metabolism and HMGR in the breast cancer cell lines T47D and MCF7, effectively reducing aldehyde dehydrogenase activity and mammosphere formation. It also blocks activation of stem cell-associated signaling pathways, including STAT1/3, Notch, and WNT/beta-catenin, thereby inhibiting Rho-GDI signaling. High levels of HMGR mRNA in breast cancer patients are associated with poor clinical outcome, suggesting a potential companion diagnostic strategy for BMF-mediated personalized therapy.

Evidence strength: This evidence is entirely in vitro and preclinical. No human clinical trials have evaluated brutieridin or BMF for cancer treatment or prevention. These findings, while mechanistically interesting, cannot be extrapolated to clinical outcomes.

5.6 In Silico / Computational Studies

An in silico approach was utilized to assess the cholesterol-lowering potential of phytochemicals derived from C. bergamia. Molecular docking using AutoDock Vina of the selected phytochemicals was performed against HMG-CoA reductase (HMGR). Results reveal that eight phytochemicals from bergamot, including brutieridin, exhibited stronger (more negative) binding affinities (–9.5 to –10.0 kcal/mol) compared to the conventional HMGR inhibitor, atorvastatin (–9.2 kcal/mol). These findings are entirely computational and require experimental validation before any pharmacological conclusions can be drawn.

6. Body Systems and Health Areas

• Cardiovascular system: The bergamot is a citrus fruit native to southern Italy with traditional uses that include improving immune response and cardiovascular function. Brutieridin-containing BPF has been clinically studied for lipid modulation and cardiovascular risk biomarkers.
• Hepatic system: Experimental and epidemiological studies show that BPF ameliorates the serum lipemic profile, normalizes blood pressure, and improves non-alcoholic fatty liver disease in patients suffering from metabolic syndrome.
• Metabolic system (glucose regulation): Clinical studies have recorded reductions in fasting glucose in metabolic syndrome patients treated with BPF containing brutieridin.
• Oncological research (preclinical only): In vitro evidence points to effects on breast cancer stem cell signaling pathways, with no human data available.
• Antioxidant defense: Anti-inflammatory and antioxidant properties of bergamot flavonoids may reduce the risk of cardiovascular disease.

7. Bioavailability and Pharmacokinetics

Despite encouraging preclinical and clinical data, pharmacokinetic information on bergamot flavonoids in humans remains limited. Like other citrus flavonoids, these compounds are thought to undergo intestinal and hepatic metabolism, with glucuronidation and sulfation likely affecting their bioavailability.

A human bioavailability study using bergamot juice (BJ) examined the metabolic fate of its flavanones after ingestion. Up to 12 structurally related flavanone metabolites were identified in plasma and urine samples after BJ consumption. Their UHPLC retention times and mass spectra, as well as their occurrence in plasma and urine, were characterized. Some of these metabolites were identified by comparison with commercially available reference compounds, while others were identified based on criteria from previous studies. The main flavanones in BJ were brutieridin, naringin, neohesperidin, melitidin, neoeriocitrin, and eriodictyol-7-O-neohesperidoside-6″-O-HMG.

The bioavailability of the intact brutieridin molecule and the pharmacological relevance of its circulating metabolites have not been fully characterized, representing a significant gap in the literature.

8. Dosage Forms and Reported Dosages

As brutieridin is studied predominantly as part of BPF, the following dosages reflect BPF preparations containing brutieridin as reported in clinical studies:

• An oral dose of BPF from 500 to 1,000 mg/day for 30 to 60 days has been used across multiple clinical studies for reduction in total cholesterol, triglycerides, LDL, and increase in HDL.
• Bergamot-derived extract has been studied at oral doses from 150 mg to 1,000 mg/day of flavonoids administered from 30 to 180 days.
• Mollace et al. (2011) demonstrated that BPF was effective after administration of 500 mg/day for 30 days, and that differences between 500 mg and 1,000 mg dosages were statistically significant only for HDL cholesterol.
• In one randomized study, subjects in the BPF group received 650 mg taken twice daily (1,300 mg/day total) and subjects in the BPF Phyto group received 500 mg taken twice daily (1,000 mg/day total), both for 30 days.
• A NAFLD/metabolic syndrome study used BPF at 650 mg twice per day for 120 days.
• A 60-day open-label study in patients taking second-generation antipsychotics used BPF at a single daily dose of 500 mg/day.

There are no published clinical dosages established for isolated brutieridin as a standalone ingredient. All dosages above refer to standardized BPF preparations in which brutieridin is one of several active constituents.

9. Safety Considerations and Drug Interactions

9.1 General Tolerability

The use of bergamot in multiple clinical trials has consistently shown that it is well tolerated in studies ranging from 30 days to 12 weeks. BPF adjunctive treatment was well tolerated at 500 mg/day dosage, as shown by the lack of pharmacokinetic effects on hematic concentrations and by the dropout causes — all unrelated to adverse and/or unwanted events — confirming the safety profile observed in previous studies.

9.2 Null Results at Low Doses

Not all clinical trials have shown benefit. Results showing a significant reduction of body weight with BPF (1,000 mg/day) supplementation were not confirmed at lower doses; furthermore, findings did not confirm the beneficial effect of low-dose BPF on lipid and glycemic profiles at 500 mg/day in one specific population (second-generation antipsychotic-treated patients). This indicates that the benefits of brutieridin-containing preparations may be dose-dependent and population-specific.

9.3 CYP3A4 and Drug Interaction Risk (Bergamottin)

A key safety consideration when consuming whole bergamot preparations is the presence of bergamottin, a furanocoumarin in the fruit that is a distinct compound from brutieridin. Bergamottin (BG), a component found in grapefruit and in bergamot, is a mechanism-based inactivator of CYP3A4 and contributes, in part, to the grapefruit juice–drug interaction. Grapefruit is a moderate to strong inactivator of CYP3A4, which metabolizes up to 50% of marketed drugs. The inhibitory effect is mainly attributed to furanocoumarins present in the fruit, irreversibly inhibiting preferably intestinal CYP3A4 as suicide inhibitors. Effects on CYP3A4 victim drugs can still be measured up to 24 hours after grapefruit juice consumption.

This CYP3A4-interaction risk is attributable to bergamottin (a furanocoumarin), not to brutieridin (a flavanone glycoside) directly. Nonetheless, when brutieridin is consumed in the form of whole bergamot juice, polyphenolic fraction, or preparations that retain the furanocoumarin fraction, the CYP3A4 interaction risk applies to the preparation as a whole. Preparations rigorously stripped of furanocoumarins would not be expected to carry this same risk.

9.4 Interaction with Statins (Co-Administration)

A clinical study suggests that a combination of rosuvastatin and BPF was safe when taken together for 30 days. However, further research beyond 30 days would be needed to determine long-term safety of this combination. The theoretical concern relates to the additive HMGR inhibition that could amplify statin-class adverse effects (e.g., myopathy), but this has not been demonstrated in the published clinical trials to date.

9.5 Liver Enzymes

Studies using BPF at doses up to 1,300 mg/day for 30–120 days have not reported clinically significant liver enzyme elevations in published trial data. Studies that monitored ALT and AST as outcomes have used BPF 650 mg twice daily over 120 days in patients with metabolic syndrome and NAFLD without documenting hepatotoxic signals. However, long-term safety data beyond 6 months with brutieridin-containing preparations remain limited.

10. Current Research Landscape and Evidence Summary

Brutieridin occupies a scientifically compelling but evidentially preliminary position. Its structural homology to the HMG moiety of statins provided the initial impetus for research, and computational, in vitro, animal, and limited human clinical studies have generated a coherent — if not yet definitive — mechanistic and clinical picture. The primary evidence base consists of studies on BPF as a mixture, making it impossible to attribute outcomes exclusively to brutieridin.

Although BPF cannot be proposed as a substitute for statins in patients at high cardiovascular risk, it offers an alternative for lower-risk populations. The lack of large, long-term, independently funded randomized controlled trials; the absence of standardized brutieridin content in commercial preparations; limited pharmacokinetic characterization in humans; and the attribution of clinical outcomes to a complex polyphenolic mixture rather than to brutieridin in isolation are all significant gaps that future research will need to address.

References

• Di Donna L et al. (2009). Statin-like Principles of Bergamot Fruit (Citrus bergamia): Isolation of 3-Hydroxymethylglutaryl Flavonoid Glycosides. Journal of Natural Products, 72(7), 1352–1354. PMID 19572741.
• Leopoldini M et al. (2010). On the Inhibitor Effects of Bergamot Juice Flavonoids Binding to the 3-Hydroxy-3-methylglutaryl-CoA Reductase (HMGR) Enzyme. Journal of Agricultural and Food Chemistry, 58(19), 10768–10773. PMID 20843083.
• Di Donna L et al. (2011). Recycling of industrial essential oil waste: Brutieridin and Melitidin, two anticholesterolaemic active principles from bergamot albedo. Food Chemistry, 125(2), 438–441.
• Navarro V et al. (2019). Clinical application of bergamot (Citrus bergamia) for reducing high cholesterol and cardiovascular disease markers. PMC6497409.
• Mannucci C et al. (2017). Efficacy of bergamot: From anti-inflammatory and anti-oxidative mechanisms to clinical applications. PMC6392855.
• Bruno A et al. (2017). Low-Dose of Bergamot-Derived Polyphenolic Fraction (BPF) Did Not Improve Metabolic Parameters in Second Generation Antipsychotics-Treated Patients. Frontiers in Pharmacology. PMC5387046.
• Janda E et al. (2021). Enjoy your journey: the bergamot polyphenols from the tree to the cell metabolism. PMC8569986.
• Bergamot Byproducts: A Sustainable Source to Counteract Inflammation. PMC10819577.
• Analytical Profile and Antioxidant and Anti-Inflammatory Activities of the Enriched Polyphenol Fractions Isolated from Bergamot Fruit and Leave. PMC7908980.
• Bioavailability of Bergamot (Citrus bergamia) Flavanones and Biological Activity of Their Circulating Metabolites in Human Pro-Angiogenic Cells. PMC5748778.
• Biological effects of bergamot and its potential therapeutic use as an anti-inflammatory, antioxidant, and anticancer agent. PMC10114982.
• The effect of bergamot polyphenolic fraction on lipid transfer protein system and vascular oxidative stress in a rat model of hyperlipemia. PMC6525455.
• Citrus bergamia essential oil: from basic research to clinical application. PMC4345801.
• Structural Characterization of Peripolin and Study of Antioxidant Activity of HMG Flavonoids from Bergamot Fruit. PMC9598738.
• Mechanisms Underlying the Anti-Inflammatory Activity of Bergamot Essential Oil and Its Antinociceptive Effects. PMC7356015.
• Fiorillo M et al. (2018). Bergamot natural products eradicate cancer stem cells (CSCs) by targeting mevalonate, Rho-GDI-signalling and mitochondrial metabolism. PMID 29626418.
• Defining the Cholesterol Lowering Mechanism of Bergamot (Citrus bergamia) Extract in HepG2 and Caco-2 Cells. Nutrients 2021, 13(9), 3156.
• Unveiling the Power of Bergamot: Beyond Lipid-Lowering Effects. Nutrients 2025, 17(11), 1871.
• Biological effects of bergamot and its potential therapeutic use as an anti-inflammatory, antioxidant, and anticancer agent. Pharmaceutical Biology 2023.
• Effect of bergamot on lipid profile in humans: A systematic review. Critical Reviews in Food Science and Nutrition 2020.
• Cicero AF et al. Comparative effect of a nutraceutical compound based on a flavonoid complex from bergamot on plasma lipids, glucose metabolism, and liver enzymes: a 3-arm, double-blind, placebo-controlled, randomized clinical trial. Archives of Medical Science.
• The Hepatic Effects of Citrus Bergamot Polyphenol Fraction (BPF) on Patients with Non-alcoholic Fatty Liver Disease and Metabolic Syndrome. Journal of Clinical Lipidology 2015.
• Identification of the Residue in Human CYP3A4 That Is Covalently Modified by Bergamottin and the Reactive Intermediate That Contributes to the Grapefruit Juice Effect. PMC3336797.
• Fuhr LM et al. (2023). Physiologically Based Pharmacokinetic Modeling of Bergamottin and 6,7-Dihydroxybergamottin to Describe CYP3A4 Mediated Grapefruit-Drug Interactions. Clinical Pharmacology & Therapeutics, 114, 470–482.
• History, Ethnopharmacology and Therapeutic Potential of Bergamot (Citrus bergamia Risso & Poit.). International Society for Ethnopharmacology.
• Folk medicine used to heal malaria in Calabria (southern Italy). PMC2949813.
• The Evaluation of Citrus bergamia Phytochemicals as Potential Cholesterol-Lowering Agents against HMG-CoA Reductase: An In Silico Molecular Docking Study. MDPI 2024.
• Effect of Citrus bergamia extract on lipid profile: A combined in vitro and human study. Phytotherapy Research 2023.
• Brutieridin — HandWiki Chemistry entry (with primary literature references).